Targeting cuproplasia and cuproptosis in cancer
Nature Reviews Clinical Oncology, Published online: 14 March 2024; doi:10.1038/s41571-024-00876-0Copper is an essential trace element with inherent redox properties and fundamental roles in a diverse range of biological processes; therefore, maintaining copper homeostasis is crucial. In this Review, the authors discuss new insights into the mechanisms by which disrupted copper homeostasis contributes to tumour initiation and development, including the recently defined concepts of cuproplasia (copper-dependent cell growth and proliferation) and cuproptosis (a mitochondrial pathway of cell death triggered by excessive copper...
Source: Nature Reviews Clinical Oncology - March 14, 2024 Category: Cancer & Oncology Authors: Daolin Tang Guido Kroemer Rui Kang Source Type: research

The promise of AI in personalized breast cancer screening: are we there yet?
Nature Reviews Clinical Oncology, Published online: 12 March 2024; doi:10.1038/s41571-024-00877-zThe benefits and potential harms of mammography-based screening for breast cancer are often a matter of debate. Here, I discuss the promises and limitations of a recent study that tested an artificial intelligence-based tool for the detection of breast cancer in digital mammograms in a large, prospective screening setting. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 12, 2024 Category: Cancer & Oncology Authors: Despina Kontos Source Type: research

FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma
Nature Reviews Clinical Oncology, Published online: 08 March 2024; doi:10.1038/s41571-024-00880-4FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 8, 2024 Category: Cancer & Oncology Authors: David Killock Source Type: research

Non-inferiority of simple versus radical hysterectomy in low-risk cervical cancer
Nature Reviews Clinical Oncology, Published online: 06 March 2024; doi:10.1038/s41571-024-00879-xNon-inferiority of simple versus radical hysterectomy in low-risk cervical cancer (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Pegargiminase improves outcomes in nonepithelioid MPM
Nature Reviews Clinical Oncology, Published online: 04 March 2024; doi:10.1038/s41571-024-00878-yPegargiminase improves outcomes in nonepithelioid MPM (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 4, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Pegargiminaseimproves outcomes in nonepithelioid MPM
Nature Reviews Clinical Oncology, Published online: 04 March 2024; doi:10.1038/s41571-024-00878-yPegargiminaseimproves outcomes in nonepithelioid MPM (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - March 4, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine
Nature Reviews Clinical Oncology, Published online: 29 February 2024; doi:10.1038/s41571-024-00870-6Increasing evidence indicates that signalling networks activated downstream of oncogenic alterations contribute fundamentally to cancer immune evasion, including by promoting the accumulation of regulatory T (Treg) cells and other immunosuppressive cells in the tumour microenvironment (TME). Herein, the authors discuss the mechanisms via which cancers engage Treg cells to evade antitumour immunity, as well as the characteristics of Treg cells in the TME and their roles in resistance to immune-checkpoint inhibitors. Consideri...
Source: Nature Reviews Clinical Oncology - February 29, 2024 Category: Cancer & Oncology Authors: Shogo Kumagai Kota Itahashi Hiroyoshi Nishikawa Source Type: research

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Nature Reviews Clinical Oncology, Published online: 29 February 2024; doi:10.1038/s41571-024-00868-0Patients with early stage hepatocellular carcinoma typically undergo resection, liver transplantation or local ablation; however, 30–50% will have disease recurrence at 3 years. The authors of this Review describe the tumour immune microenvironment and mechanism of action of immunotherapies, and discuss the available evidence from phase II/III trials of neoadjuvant and adjuvant treatment approaches in this setting. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 29, 2024 Category: Cancer & Oncology Authors: Josep M. Llovet Roser Pinyol Mark Yarchoan Amit G. Singal Thomas U. Marron Myron Schwartz Eli Pikarsky Masatoshi Kudo Richard S. Finn Source Type: research

FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Nature Reviews Clinical Oncology, Published online: 29 February 2024; doi:10.1038/s41571-024-00869-zFGFR inhibitors are now approved for use in patients with advanced-stage urothelial carcinoma, cholangiocarcinoma and myeloid or lymphoid neoplasms that harbour certain FGFR alterations. Nonetheless, challenges such as tolerability and acquired resistance limit the clinical potential of these agents. In this Review, the authors summarize the available clinical data on FGFR inhibitors, describe promising novel agents and highlight future research directions that might optimize the efficacy of FGFR-targeted therapies. (Source:...
Source: Nature Reviews Clinical Oncology - February 29, 2024 Category: Cancer & Oncology Authors: Masuko Katoh Yohann Loriot Giovanni Brandi Simona Tavolari Zev A. Wainberg Masaru Katoh Source Type: research

Adjuvant chemotherapy improves OS in UTUC
Nature Reviews Clinical Oncology, Published online: 22 February 2024; doi:10.1038/s41571-024-00875-1Adjuvant chemotherapy improves OS in UTUC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 22, 2024 Category: Cancer & Oncology Authors: David Killock Source Type: research

FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit
Nature Reviews Clinical Oncology, Published online: 21 February 2024; doi:10.1038/s41571-024-00871-5In 2023, the US FDA approved several new cancer drugs and biologic agents, including seven small-molecule inhibitors, four bispecific T cell engagers, two anti-PD-1 antibodies and one cell therapy product. Regulatory focus areas included analyses of biomarker-positive subgroups that drive efficacy, equipoise in randomized controlled trials and a new authority to require confirmatory trials be underway before accelerated approval. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 21, 2024 Category: Cancer & Oncology Authors: Kelly J. Norsworthy Rosa J. Lee-Alonzo Richard Pazdur Source Type: research

Targeting ATR in patients with cancer
Nature Reviews Clinical Oncology, Published online: 20 February 2024; doi:10.1038/s41571-024-00863-5Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) is a mediator of the cellular replication stress response that, upon activation, initiates a cascade of coordinated reactions that ultimately enables DNA repair. This biological function makes ATR an attractive therapeutic target in cancers with elevated replication stress or DNA-repair deficiency. This Review discusses the currently available results from clinical trials testing ATR inhibitors as well as challenges and solutions in the development ...
Source: Nature Reviews Clinical Oncology - February 20, 2024 Category: Cancer & Oncology Authors: Natalie Y. L. Ngoi Patrick G. Pili é Daniel J. McGrail Michal Zimmermann Katharina Schlacher Timothy A. Yap Source Type: research

Tabelecleucel is effective in EBV-positive lymphoproliferative disease
Nature Reviews Clinical Oncology, Published online: 19 February 2024; doi:10.1038/s41571-024-00873-3Tabelecleucel is effective in EBV-positive lymphoproliferative disease (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 19, 2024 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

KN046 shows tolerability and activity in TNBC
Nature Reviews Clinical Oncology, Published online: 16 February 2024; doi:10.1038/s41571-024-00872-4KN046 shows tolerability and activity in TNBC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - February 16, 2024 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Dendritic cells as orchestrators of anticancer immunity and immunotherapy
Nature Reviews Clinical Oncology, Published online: 07 February 2024; doi:10.1038/s41571-024-00859-1Dendritic cells (DCs) are antigen-presenting cells that function at the interface between innate and adaptive immunity, thereby acting as key mediators of antitumour immune responses and immunotherapy efficacy. In this Review, the authors outline the emerging complexity of intratumoural DC states that is being revealed through single-cell analyses as well as the contributions of different DC subsets to anticancer immunity and the activity of immune-checkpoint inhibitors. The authors also discuss advances in the development o...
Source: Nature Reviews Clinical Oncology - February 7, 2024 Category: Cancer & Oncology Authors: Ignacio Heras-Murillo Irene Ad án-Barrientos Miguel Gal án Stefanie K. Wculek David Sancho Source Type: research